ADAMAS PHARMACEUTICALS INC's ticker is ADMS and the CUSIP is 00548A106. A total of 117 filers reported holding ADAMAS PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $53,000 | +10.4% | 10,000 | 0.0% | 0.01% | 0.0% |
Q1 2021 | $48,000 | -95.5% | 10,000 | -95.9% | 0.01% | -95.7% |
Q4 2020 | $1,063,000 | -27.5% | 245,399 | -31.0% | 0.16% | -37.8% |
Q3 2020 | $1,466,000 | +60.9% | 355,845 | 0.0% | 0.26% | +37.2% |
Q2 2020 | $911,000 | -21.5% | 355,845 | -11.4% | 0.19% | -40.5% |
Q1 2020 | $1,161,000 | -23.2% | 401,845 | +0.8% | 0.32% | +4.9% |
Q4 2019 | $1,511,000 | -48.6% | 398,609 | -30.7% | 0.31% | -58.6% |
Q3 2019 | $2,941,000 | -13.9% | 574,886 | +4.4% | 0.74% | -1.2% |
Q2 2019 | $3,415,000 | -10.5% | 550,836 | +2.6% | 0.75% | -10.4% |
Q1 2019 | $3,817,000 | +89.2% | 536,836 | +127.4% | 0.84% | +49.9% |
Q4 2018 | $2,017,000 | -73.4% | 236,124 | -37.8% | 0.56% | -61.9% |
Q3 2018 | $7,596,000 | -18.3% | 379,424 | +5.5% | 1.46% | -22.2% |
Q2 2018 | $9,294,000 | +76.5% | 359,796 | +63.3% | 1.88% | +78.5% |
Q1 2018 | $5,265,000 | +54.9% | 220,296 | +119.6% | 1.05% | +52.0% |
Q4 2017 | $3,399,000 | – | 100,300 | – | 0.69% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 2,601,351 | $43,963,000 | 9.03% |
Granite Point Capital Management, L.P. | 256,031 | $4,327,000 | 3.45% |
Opaleye Management Inc. | 285,000 | $4,817,000 | 2.84% |
Brenner West Capital Advisors | 1,221,463 | $20,643,000 | 2.28% |
ARMISTICE CAPITAL, LLC | 536,000 | $9,058,000 | 2.14% |
NEXTHERA CAPITAL LP | 151,670 | $2,563,000 | 1.50% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 185,234 | $3,130,000 | 1.41% |
Cheyne Capital Management (UK) LLP | 144,765 | $2,448,000 | 1.38% |
SPHERA FUNDS MANAGEMENT LTD. | 270,000 | $4,563,000 | 1.16% |
Mosaic Family Wealth, LLC | 123,314 | $2,084,000 | 0.96% |